#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Nephropathy Metastatic gastric cancer Juvenile chronic myelomonocytic leukaemia Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Diabetes insipidus Congenital ectodermal dysplasia Neuroblastoma Immunodeficiency congenital Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Testicular leiomyosarcoma Nephroblastoma Cerebral amyloid angiopathy Carcinoid tumour Deafness neurosensory Juvenile psoriatic arthritis More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia Glycogen storage disease type I – Basic Information Krabbe’s disease – Life with Disease Gaucher’s disease type III – Life with Disease Alport’s syndrome – Basic Information Kearns-Sayre syndrome – Trials in Disease Pemphigoid – Life with Disease Hereditary hypophosphataemic rickets – Life with Disease Leiomyosarcoma recurrent Nephroblastoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bay 2927088 Tobevibart Moxifloxacin Hydrochloride IMB 101 Amcenestrant Nilutamide CHLOROQUINE PHOSPHATE Methionine Sym025 ULVIPRUBART Propofol Avatrombopag TUB-030 Umeclidinium Bromide Mianserin Hydrochloride Cemdisiran Ab-729 Aflibercept Opevesostat Pegaspargase More therapies…

    Learn about Your Condition

    Incisional hernia Brain stem glioma Rosai-Dorfman syndrome Psychotic behaviour Hysterectomy Stress Hepatitis B Lung adenocarcinoma stage IV Iron deficiency Viral infection Hepatic neoplasm Malignant peritoneal neoplasm Malignant melanoma of eyelid Adenocarcinoma of colon Lymphocytic leukaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Pembrolizumab, Lenvatinib, and Chemotherapy for Patients with Metastatic Esophageal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal carcinoma
    Investigated Drugs:
    • ANHYDROUS CALCIUM FOLINATE
    • Cisplatin
    • Fluorouracil
    Denmark France Hungary Italy Romania Spain

  • Study on Radiotherapy with Xevinapant or Placebo for Older Patients with Advanced Head and Neck Cancer

    Not recruiting

    2 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Xevinapant
    Belgium France Germany Ireland Italy The Netherlands +3

  • Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia Denmark Finland France +7

  • Study of Radiotherapy with Cetuximab and Xevinapant for Patients with Advanced Head and Neck Cancer Unfit for High-Dose Cisplatin

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Head and neck cancer
    Investigated Drugs:
    • Xevinapant
    • Cetuximab
    France

  • Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ipilimumab
    • Cabozantinib
    • Nivolumab
    Belgium Czechia Finland France Germany Italy +3

  • Study of Mirvetuximab Soravtansine compared to standard chemotherapy in women with platinum-resistant advanced ovarian cancer with high folate receptor expression

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Peritoneal sarcoma
    • Fallopian tube cancer
    • Ovarian epithelial cancer
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • Topotecan
    • Doxorubicin Hydrochloride
    France

  • Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Tivozanib
    • Nivolumab
    Belgium Czechia France Germany Italy Poland +2

  • Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Petosemtamab
    • Pembrolizumab
    Austria Belgium Croatia Czechia France Germany +8

  • Study of Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Belzutifan
    • Favezelimab
    • Lenvatinib
    France Hungary The Netherlands Poland Spain

  • Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Doxorubicin Hydrochloride, Liposomal
    • Topotecan
    • Paclitaxel
    Czechia Finland France Germany Greece Italy +3
Previous Page
1 … 16 17 18

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!